Mynvax key facts
- Developer of novel drugs designed to be used in vaccines for respiratory viruses.
- Mynvax’s last known valuation is $29.8M.
- It has raised $12.7M; the latest was Later Stage VC ($5.6M) in May 2024.
- Notable investors include Accel, LetsVenture Technologies, Accel India, Legacy Assets, 1Crowd — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Mynvax
15+- ·The complete investor list: 15 names
- ·Watch Mynvax: the Monday email on marks, rounds and moves
Mynvax funding rounds
No funding rounds for Mynvax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Mynvax valuation
Mynvax's last known valuation is $29.8 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Mynvax investors
15 investors are on record for Mynvax, including Accel, LetsVenture Technologies, Accel India and Legacy Assets.
About Mynvax
Developer of novel drugs designed to be used in vaccines for respiratory viruses. The company's drugs specialize in the treatment of flu and infectious disease for the healthcare industry, enabling medical professionals to improve their patient's recovery.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2017
- Employees
- 28
- Website
- mynvax.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Mynvax’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.